諾唯贊(688105.SH):諾唯贊醫療變更醫療器械生產許可證
格隆匯6月22日丨諾唯贊(688105.SH)公佈,公司全資子公司南京諾唯贊醫療科技有限公司(簡稱“諾唯贊醫療”)於近日取得江蘇省藥品監督管理局換髮的《醫療器械生產許可證》(許可證編號:蘇藥監械生產許20170028號)。本次變更涉及新增生產地址與更新許可證編號。
生產地址:南京經濟技術開發區科創路紅楓科技園C2棟東段1-3層、中段1-3層、西段2-4層,南京經濟技術開發區科創路紅楓科技園D2棟9-11層,南京市棲霞區潤博路1號101,泰州高新醫藥產業園第五期標準廠房G105棟,南京經濟技術開發區金港路6號B1號;
生產範圍:III類:6840-1與致病性病原體抗原、抗體以及核酸等檢測相關的試劑,II類:22-04免疫分析設備,6840-1用於蛋白質檢測的試劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.